<DOC>
	<DOCNO>NCT02159599</DOCNO>
	<brief_summary>This open label randomize clinial trial evaluate treatment darunavir/ritonavir ( 800mg/100mg ) plus lamivudine ( 300 mg ) daily versus continue darunavir/ritonavir ( 800mg/100mg ) daily plus tenofovir/emtricitabine ( 300mg/200mg ) abacavir/lamivudine ( 600mg/300mg ) HIV infect subject suppress plasma viremia .</brief_summary>
	<brief_title>Study Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine Abacavir/Lamivudine HIV Infected Subject</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>1 . Acceptance participate study , sign informed consent document conduct study procedure . 2 . Patient HIV infection old 18 year . 3 . Treatment darunavir/ritonavir day tenofovir/emtricitabine abacavir/lamivudine least 4 week moment screen 4 . Plasma HIV RNA level 50 copy / ml least 6 month ( two separate measurement least 6 month viremia &lt; 50 copy / ml ) . 5 . HbsAg negative 1 . Pregnant breastfeed woman 2 . Evidence Lamivudine resistance ( previous genotype mutation M184V/I K65R ) and/or darunavir ( population genotype show follow mutation : V11I , V32I , L33F , I47V , I50V , I54L/M , G73S , T74P , L76V , I84V , L89V ) . 3 . History virology failure ( two consecutive viral load 200 copies/ml ) patient receive regimen lamivudine emtricitabine , follow exception : Do consider exclusion criterion genotype perform time failure demonstrate resistance lamivudine darunavir ( see criterion 2 ) . Do consider exclusion criterion absence genotype episode turn maintain viral load &lt; 50 copy / ml treatment compose lamivudine emtricitabine + nucleoside + nonnucleoside . 4 . History abandonment treatment include lamivudine emtricitabine , follow exception : Viral load prior abandonment &lt; 50 copy / ml subsequent reintroduction treatment another treatment consist lamivudine emtricitabine + nucleoside + nonnucleoside return maintain viral load 50 copy / ml . 5 . Previous treatment bitherapy monotherapy lamivudine emtricitabine 6 . Previous treatment bitherapy monotherapy regimen protease inhibitor terminate viral rebound , absence genotypic resistance test available viral rebound allow discard resistance mutation either drug use . 7 . The use concomitant medication permit 8 . Presence active acute infection , include opportunist infection judge investigator difficult participation trial 9 . Any laboratory result follow : hemoglobin &lt; 8,0 g/dl ; neutrophil &lt; 750 cells/µl ; platelet &lt; 50.000 cell/µl ; creatinine ≥ 1,5 ULN ( upper limit normal ) 10 . Any clinical analytic event , investigator judgment , condition patient safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>